CD52 and myeloid sarcoma: Alemtuzumab is another approved monoclonal antibody for relapsing MS, which acts by binding to CD52 expressed on T and B cells, resulting in depletion of CD52 positive T and B cells followed by subsequent repopulation [85, 86].